Thermo Fisher expands center to ease clinical trial logistics

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ Hero Images)
(Image: Getty/ Hero Images)

Related tags facility Logistics Clinical trial Oncology Gene therapy Cell therapy

Thermo Fisher opened a new business center and biorepository along with an expanded distribution center, to help support mounting demand for clinical trial supply chain logistics.

Located in Frederick, Maryland, the site will serve as a hub for contract development and manufacturing organization (CDMO) Thermo Fisher’s business aiming to accommodate its future growth.

The facility expanded by more than 190,000 square feet making it the largest building on the company’s Frederick campus. With the expansion, another 22,000 square feet have been added to accommodate future advancements in automation. In total, Thermo Fisher’s investment in the campus has reached nearly $10m.

Additionally, the company added a 77,000 square foot facility, Cryo-Innovation Center and National Cancer Institute Repository for Clinical Trials. The center will be a third-party logistics site to support clinical trials as well as commercial cell and gene therapy developments. 

Dave Meadows, VP and general manager for Thermo Fisher Scientific said in a press release, “The Frederick campus will serve as Thermo Fisher’s clinical and commercial hub for cell and gene therapy treatments to meet the growing demand from the global healthcare industry.”

The new facility will act as a consolidation of several smaller facilities on the campus to create a center of excellence for clinical research sample storage. Central to the facility is a biorepository supporting the National Cancer Institute and its ongoing research.

Thermo Fisher recently stepped into a pilot program​ organized by the US Food and Drug Administration to advance policies in the drug development process. At the time a company representative told us that mitigation of risk and expediency needs to be the highest priority in all aspects of trial conduct. 

Related topics Cell & Gene Therapies

Related news

Follow us